Integrum Appoints Martin Hillsten as New CEO
Integrum AB (publ) has recently announced the appointment of Martin Hillsten as its new Chief Executive Officer, effective immediately. Martin takes over from Scott Flora, who served as acting CEO and will continue to provide support for US marketing efforts in an advisory role while remaining on the Board of Directors.
Strategic Direction Under New Leadership
Under Martin Hillsten's leadership, Integrum is poised to implement a fresh strategic direction designed to accelerate the market penetration of the innovative OPRA Implant System. This new strategy will prioritize growth in the United States and certain select European countries, focusing on strategic partnerships with Centers of Excellence. Additionally, the plan aims to strengthen the aftermarket approach while streamlining operations, with projected cost savings reaching up to SEK 20 million annually by early 2026.
Martin Hillsten’s Background and Experience
Martin Hillsten, born in 1978, holds a Bachelor of Business Administration from the University of Lincoln, UK. He brings with him over 20 years of experience in the life sciences sector, specializing in implant products and diagnostic imaging. Previously, he served as CEO of Integration Diagnostics, where he led initiatives for the development, production, and marketing of products that measure implant stability and bone tissue integration. Notably, approximately 70% of this company's revenue is generated from the US market, highlighting Martin's extensive US market experience. Furthermore, he has held significant sales and marketing roles at Bracco Diagnostics and currently holds 42,000 shares in Integrum.
Vision for the Future
During this transitional phase, Scott Flora's contributions as acting CEO established a strong foundation for the company's growth trajectory with the OPRA Implant System. Martin Hillsten's vast expertise in medical device sales and marketing is seen as a crucial asset that will help Integrum navigate this strategic shift. The company aims to position itself as a leader in bone-anchored implant systems, enhancing value for both patients and shareholders alike.
Comments from Leadership
Beng Sjöholm, Chairman of the Board, expressed confidence in Martin's capability to leverage the new strategy initiated by the Board. He stated, "Martin's extensive experience in sales and marketing of advanced medical devices, along with his commitment to creating value for patients and shareholders, will be vital as we further establish Integrum as a world leader in our field."
Martin Hillsten’s Commitment
Upon his appointment, Hillsten remarked, "I have been following Integrum's journey closely and am incredibly impressed by the revolutionary OPRA Implant System. The strategic shift towards optimizing our sales and marketing efforts can deliver significant shareholder value while enhancing the mobility for a growing number of amputees. My focus will be on driving sales growth while achieving cost efficiencies that will substantially improve our operating margins."
Frequently Asked Questions
Who is the newly appointed CEO of Integrum?
The new CEO of Integrum is Martin Hillsten, who takes over from Scott Flora.
What is the strategic focus under the new CEO?
The strategic focus is to enhance market penetration of the OPRA Implant System, particularly in the US and select European nations.
How much cost savings does Integrum expect from its new strategy?
Integrum anticipates cost savings of up to SEK 20 million annually when the strategy is fully implemented.
What previous experience does Martin Hillsten bring to Integrum?
Martin has over 20 years of experience in life sciences, specifically in sales and marketing of medical devices, and has previously served as CEO of Integration Diagnostics.
What role will Scott Flora play after Martin Hillsten's appointment?
Scott Flora will support the marketing strategy in an advisory capacity and remain on the Board of Directors.
